AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04588532
Drug: BAM8-22
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine Adrenal Medulla will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
Trial: NCT04588532
Drug: Cowhage (Mucuna Pruriens)
RxNorm normalized name: cowhage (Mucuna pruriens)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cowhage spicules will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
Trial: NCT03778359
Drug: Progestins
RxNorm normalized name: PROGESTINS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Progestins.
Trial: NCT04551352
Drug: RO7293583
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7293583 will be administered at a dose and per schedule as specified for the respective cohort.
Trial: NCT02571127
Drug: Hidra1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parameters: Vaginal health index (VHI) : The parameter of efficiency : a vaginal moisture ; Will Measured through the VHI : 1 = none / inflamed area ; 2 = no / NOT inflamed surface ; 3 = minimal, 4 = moderate and 5 = normal.~Will be described through the Media and Standard Deviation or median and interquartile rank , as Minimum and Maximum.~Scala: pH tape: It will be measured by its own value. Questionnaire: Sexual Function Index female (FSFI): internationally validated questionnaire with single answers for patient.
Trial: NCT03823404
Drug: COR388 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID (twice daily)
Trial: NCT03823404
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID
Trial: NCT02334787
Drug: 0.3% OPA-15406 Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 0.3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
Trial: NCT02334787
Drug: 1% OPA-15406 Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose
Trial: NCT02334787
Drug: 3% OPA-15406 Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
Trial: NCT02334787
Drug: Placebo Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration periodriod, subjects were treated with assigned placebo ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned placebo ointment twice daily for 14 days and assessed until 48 hours post dose.
Trial: NCT04085367
Drug: MAL 16.8% cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day light photodynamic therapy with MAL 16.8% cream
Trial: NCT04085367
Drug: MAL Vehicle Cream
RxNorm normalized name: maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day light photodynamic therapy with MAL vehicle cream
Trial: NCT03729362
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglustat matching placebo was administered orally 1 hour prior to alglucosidase alfa infusion Q2W.
Trial: NCT00847171
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 200mg/m2 IV in NS 100ml over 30 minutes on Day -1 ONLY. Note: there are no dose modifications for Cyclophosphamide.
Trial: NCT01129102
Drug: NPC-01
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethisterone 1mg, Ethinyl estradiol 0.02mg
Trial: NCT01129102
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for NPC-01
Trial: NCT06190340
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration orally.
Trial: NCT02103725
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01273376
Drug: RX-10100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release tablet, taken twice daily for 8 weeks
Trial: NCT00124475
Drug: alitretinoin
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05436769
Drug: Klaribact 500 mg Clarithromycin Tablet
RxNorm normalized name: clarithromycin 500 MG
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.
Trial: NCT05436769
Drug: Klaricid 500 mg Clarithromycin Tablet
RxNorm normalized name: clarithromycin 500 MG
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.
Trial: NCT04573751
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy as follows: adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
Trial: NCT04573751
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard therapy plus epinephrine as follows: epinephrine, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
Trial: NCT00943709
Drug: therapeutic insulin
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given subcutaneously
Trial: NCT01291199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo p.o. 6 weeks bid
Trial: NCT00068211
Drug: ILX651
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00503932
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m\^2 by mouth (PO) twice daily on days receive radiation.
Trial: NCT03748641
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo once daily.
Trial: NCT00862303
Drug: IL-2/IFN-α
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive treatment of IL-2 or IFN-α.
Trial: NCT01878643
Drug: vancomycin or gentamicin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Choice of antibiotic is determined by Gram stain of sputum.The antibiotic is administered via nebulization through the ventilator circuit every 8 hours
Trial: NCT01878643
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline administered to patient via nebulization
Trial: NCT00616434
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IM injection, self-administered per protocol.
Trial: NCT04350346
Drug: Motilitone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Ingredients and content: corydalis tuber, pharbitis seed 50% EtOH extracts 30mg~2. Dosage method: Usually, adults take 1 tablet 3 times a day orally before meals.~3. Pharmacological action:~   * It stimulates 5-HT4 receptor as a gastrointestinal motility accelerator to increase acetylcholine secretion and contract smooth muscle.~     * Stimulates stomach smooth muscle contraction by suppressing the effect of dopamine on acetylcholine secretion by inhibiting D2 receptor ③ It shows a pharmacological action that stimulates gastrointestinal movement by acting in combination with 5-HT1A / B receptor.
Trial: NCT03442764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04021498
Drug: Simvastatin 40mg
RxNorm normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: phase III, triple-blind randomised placebo-controlled trial comparing simvastatin 40 mg/day versus placebo (lactose). One hundred and fifty eight patients with recurrent AP (at least 2 episodes) will be included (79 per arm of treatment). Treatment and follow-up will last for 12 months.
Trial: NCT03387644
Drug: Control placebo (C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets one hour before the procedure as premedication.
Trial: NCT02612051
Drug: GSK3008348 Nebuliser solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebuliser solution formulated at 5000 mcg/mL with 5% mannitol, citric acid, sodium citrate and water for injection, pH adjusted using Hydrochloric acid or Sodium hydroxide to the target pH 5.4 +/- 0.4. 4 ml of diluted dose of appropriate concentration will be administered by nebulisation.
Trial: NCT00738192
Drug: Fentanyl citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 0.5 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
Trial: NCT00738192
Drug: Sufentanil citrate
RxNorm normalized name: Sufentanil Citrate
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.05 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
Trial: NCT02813135
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02813135
Drug: Peposertib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01917578
Drug: TAC,TC,TA,CAF,CEF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. TAC:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 3 cycles)~2. TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 2 cycles)~3. TA:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1(Cycled every 21 days for 2 cycles)~4. CAF:Cyclophosphamide 100 mg/㎡ po days 1-14 + Doxorubicin 30 mg/㎡ iv days 1,8 +5-fluorouracil 500 mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)~5. CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)
Trial: NCT01017367
Drug: MDX-1100
RxNorm normalized name: hydrocortisone acetate Topical Gel [Cortisil MDX]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDX-1100 10 mg/kg i.v. over 60 minutes on days 1, 15, 29, 43, 57 and 71
Trial: NCT01017367
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01917578
Drug: AC-P,TEC,AC,TC,TCH,CEF,TAC,CAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. AC-P:Doxorubicin 60 mg/㎡ iv day 1 +Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 14 days for 4 cycles)→ Paclitaxel 175mg/㎡ by 3h iv infusion day 1(Cycled every 14 days for 4 cycles) or Paclitaxel 80mg/㎡ by 1h iv infusion weekly for 12 wks.~2. TEC:Docetaxel 75 mg/㎡ iv day 1 + Epirubicin 75 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 6 cycles)~3. AC:Doxorubicin 60 mg/㎡ in day 1 + Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 21 days for 4 cycles)~4. TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 4 cycles)~5. TCH:Docetaxel 75 mg/㎡ iv day 1 + Carboplatin AUC 6 iv day1(Cycled every 21 days for 6 cycles) + Trastuzumab 4 mg/kg iv wk 1 → Trastuzumab 2 mg/kg iv for 17 wks → Trastuzumab 6 mg/kg iv every 3 wks to complete 1 year.~6. CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 6 cycles)
Trial: NCT02477007
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg).
Trial: NCT02477007
Drug: paracetamol + ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Paracetamol will be an oral solution of 30 mg/ml. The doses of paracetamol will be 15 mg/kg (maximum dose: 1g) Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg).
Trial: NCT02477007
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will have the closest flavour, smell and aspect to the active substances, respectively paracetamol and ibuprofen. Placebo will be prepared in bottles with a fake label of active substances for a better blinding both for the nurse and the patient. Labels will be hiding by a mask.
Trial: NCT01480271
Drug: 20ng GSK2445053
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20ng GSK2445053 administered intranasally
Trial: NCT01480271
Drug: 100ng GSK2445053
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100ng GSK2445053 administered intranasally
Trial: NCT01480271
Drug: 1000ng GSK2445053
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000ng GSK2445053 administered intranasally
Trial: NCT01480271
Drug: 2000ng GSK2445053
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000ng GSK2445053 administered intranasally
Trial: NCT01480271
Drug: 4000ng GSK2445053
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4000ng GSK2445053 administered intranasally
Trial: NCT01480271
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intranasally
Trial: NCT02184507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One sachet of placebo was consumed daily for 7 days before surgery and 30 days after CABG
Trial: NCT00362856
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule
Trial: NCT03916510
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is a chemotherapy drug licensed for use in rectal cancer, it is a non-cytotoxic pre-cursor of the cytotoxic 5-fluorouracil. Due to Capecitabine not being taken on Enadenotucirev dosing days it is considered an investigational medicinal product within this trial.
Trial: NCT00741325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02224599
Drug: Cyclophosphamide Pill
RxNorm normalized name: cyclophosphamide Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be given low-dose cyclophosphamide by mouth for 5 days starting 5 to 7 days prior to the vaccine cycle.
Trial: NCT03402178
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution (0.2 mg) or tablet (0.5 mg and 5 mg) matched to E2082.
Trial: NCT02067442
Drug: oral acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 milligrams given orally before surgery
Trial: NCT02067442
Drug: intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 milligrams of intravenous acetaminophen given before surgery
Trial: NCT02616614
Drug: Clindamycin/benzoyl peroxide gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic Clindamycin/benzoyl peroxide gel for treating acne
Trial: NCT00588536
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX 30mg/m2 (or 1mg/kg for infants) orally, given in three equally divided doses at 0,8, and 16hrs
Trial: NCT00588536
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5mg orally at 36,48, and 60hrs (or 12 hrs after the dose of 6-TG and then every 12 hrs for a total of 3 doses)
Trial: NCT06416735
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration of a single dose of 5 or 10 mg of Amiloride (based on body weight) After oral intake of the drug, the increase in sodium in the urine ends within 8 hours
Trial: NCT02036528
Drug: Gentamicin Topical Gel
RxNorm normalized name: gentamicin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02036528
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003061
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01308983
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amiloride 10 mg orally once a day for 16 weeks
Trial: NCT03016533
Drug: ABC/DTG/3TC immediate release tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABC/DTG/3TC immediate release tablets will be provided as biconvex, oval tablets containing 600 mg ABC, 50 mg DTG and 300 mg 3TC.
Trial: NCT04459767
Drug: Vupanorsen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg subcutaneous injection
Trial: NCT04459767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT00268151
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00054171
Drug: aminolevulinic acid hydrochloride
RxNorm normalized name: Aminolevulinic Acid Hydrochloride
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01000545
Drug: placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 soft-gel capsules per day to be taken orally for 12 months
Trial: NCT00871598
Drug: BTT1023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous, three infusions over three weeks
Trial: NCT00871598
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous, three infusions over three weeks
Trial: NCT00871598
Drug: BTT1023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test challenge
Trial: NCT03424005
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered 1250 mg/m\^2 orally twice daily on Days 1-14, of each 21 day cycle.
Trial: NCT01318733
Drug: CD07805/47 gel 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this open-label study, all subjects will receive treatment with CD07805/47 gel 0.5% applied once daily, for up to 12 months.
Trial: NCT03503227
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily oral low dose prednisolone (10 mg/day) :a glucocorticoid
Trial: NCT00082927
Drug: ibandronate sodium
RxNorm normalized name: Ibandronate Sodium
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02179775
Drug: Quince's oxymel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02179775
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00448682
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01208831
Drug: LDE225
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02017600
Drug: ND-420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ND-420 50 mg/m2 on day1
Trial: NCT02017600
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fluorouracil 700 mg/m2 daily, day1 to day4
Trial: NCT00802529
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 transtympanic injections at an interval of two weeks. If there is significant hearing loss before second injection, it will be replaced by normal saline in double blinded fashion.
Trial: NCT02604017
Drug: ABT-493/ABT-530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; ABT-493 coformulated with ABT-530
Trial: NCT02195687
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline (placebo) injected into bilateral Crow's Feet Line areas.
Trial: NCT01117051
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00673270
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 mg of intravenous hydrocortisone
Trial: NCT00673270
Drug: Placebo of Hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of isotonic saline solution
Trial: NCT02545231
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
Trial: NCT03280927
Drug: Jublia®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jublia® topical solution
Trial: NCT00882401
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo at same dose schedule as ergocalciferol